Rimegepant

Phase 3

PFIZER (PFE)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Q4 '26

PFEPhase 3$160.0B

Rimegepant Phase 3 Est. Readout

Rimegepant• Acute Migraine723

Q4 2026~QConfirmedSTALE

CT.gov

00%

Oct '26

PFEPhase 3$160.0B

Rimegepant Phase 3 Est. Readout

Rimegepant• Acute Migraine200

Oct 2026~Confirmed

CT.gov

00%

Competitive Landscape

0 competitors in Acute Migraine

View Full Landscape

Drug Information

Target Indication

Acute Migraine

Clinical Trial

NCT04574362

Last updated: 12/13/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA4/25/2022

Vydura

Vydura is indicated for the Acute treatment of migraine with or without aura in adults; Preventative treatment of episodic migraine in adults who have at least 4 migraine attacks per month.

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

PFE

PFIZER

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

FSME-IMMUN NEW 0.25 mlPhase 3

Tick-borne Encephalitis

AvelumabPhase 3

Urothelial Cancer

HibPhase 3

Pneumococcal Infections

Experimental 20-valent pneumococcal conjugate vaccine (20vPnC)Phase 3

Pneumococcal Disease

ElotuzumabPhase 3

Multiple Myeloma

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts